Increased EZH2 expression was initially demonstrated in prostate and breast cancer based on microarray studies which supported the hypothesis that the upregulation of this protein is associated with advanced stage and poor prognosis [11, 12]. This evidence concerns the gene EZH2 and breast carcinoma.